KETOROLAC SOLUTION

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

KETOROLAC TROMETHAMINE

Dostupné z:

AA PHARMA INC

ATC kód:

S01BC05

INN (Medzinárodný Name):

KETOROLAC

Dávkovanie:

0.5%

Forma lieku:

SOLUTION

Zloženie:

KETOROLAC TROMETHAMINE 0.5%

Spôsob podávania:

OPHTHALMIC

Počet v balení:

5ML/10ML

Typ predpisu:

Prescription

Terapeutické oblasti:

NONSTEROIDAL ANTI-INFLAMMATORY AGENTS

Prehľad produktov:

Active ingredient group (AIG) number: 0121995003; AHFS:

Stav Autorizácia:

APPROVED

Dátum Autorizácia:

2012-07-06

Súhrn charakteristických

_KETOROLAC (ketorolac tromethamine ophthalmic solution) _
_Page 1 of 21 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
KETOROLAC
Ketorolac Tromethamine Ophthalmic Solution
Solution, 0.5% w/v, for ophthalmic use
with benzalkonium chloride 0.01% w/v as preservative
Topical Non-Steroidal Anti-Inflammatory Agent
ATC code: S01BC05
AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Initial Authorization:
May 27, 2002
Date of Revision:
August 28, 2023
Submission Control Number.: 273938
_KETOROLAC (ketorolac tromethamine ophthalmic solution) _
_Page 2 of 21 _
RECENT MAJOR LABEL CHANGES
None at the time of the most recent authorization.
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics:
....................................................................................................................
4
1.2
Geriatrics:
....................................................................................................................
4
2
CONTRAINDICATIONS
....................................................................................................
4
4
DOSAGE AND ADMINISTRATION
....................................................................................
4
4.1
Dosing Considerations
................................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
........................................................... 4
4.4
Administration
..........